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ABSTRACT
Plasmocytoid variant urothelial carcinoma (PVUC) of the urinary bladder is a rare histological variant of transitional 
cell carcinoma. Data regarding PVUC shows that this neoplasia presents a distinctive clinical outcome represented by 
aggressive behavior and poor survival rate. The authors report a case of a 57-year-old male patient with a 3-month history 
of hematuria and pelvic pain. Radical cystectomy with lymphadenectomy was performed and pathological examination 
showed a pT3pN0 PVUC of the bladder. The patient remained free of recurrence for 8 months, but the disease recurred 
involving the abdominal wall and subcutaneous tissue. Chemotherapy provided a positive clinical response and relief of 
symptoms. The authors call attention to the aggressiveness of this rare variant of bladder cancer and recommend radical 
surgery and multidisciplinary management of this neoplasm.
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CASE REPORT
A 57-year-old man sought the Urology Service 
complaining of pelvic pain and hematuria for three 
months. His past medical history included heavy 
smoking. No familial history of cancer was present. The 
first diagnostic approach involved a cystoscopy, which 
revealed thickened urinary bladder mucosa. Therefore 
he was submitted to transurethral resection, which 
showed a muscle-invasive urothelial carcinoma on 
histological examination. Initial pelvic, abdominal and 
thoracic computed tomography (CT) showed bladder 
wall thickening (Figure 1) without regional or distant 
lymphadenopathy neither distant metastasis.
A radical cystectomy with lymphadenectomy 
was performed. Pathological examination showed 
plasmocytoid urothelial carcinoma invading perivesical 
adipose tissue and anterior bladder wall. (Figure 2)
The urethral margins were tumor free but 
perineural  invasion was present. No tumoral 
involvement was observed in 9 dissected lymph nodes. 
The immunohistochemistry study revealed positivity 
to cytokeratin CK7, CK20, 34bE12 and CD138. 
Napsin A, CDX-2, p63 and E-cadherin were negative. 
Pathological staging was pT3pN0. (Figure 3)
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After 8 months, the patient presented progressive 
swelling and pain in the suprapubic region and 
scrotum. CT scan showed a densification of adipose 
and muscle layers of the anterior abdominal wall 
extending to the scrotum. (Figure 4).
A biopsy of the subcutaneous adipose tissue 
confirmed poorly cohesive and plasmocytoid features 
of the carcinoma compatible with high-grade urothelial 
carcinoma. (Figure 5)
Chemotherapy (MVAC regimen) was prescribed as 
follow: methotrexate 30 mg/m2 on days 1, 15 and 22; 
vinblastine 3 mg/m2 on days 2, 15 and 22, doxorubicin 
30 mg/m2 on day 2 and cisplatin 70 mg/m2 on day 2, 
every 28 days each cycle. After 3 cycles, the patients 
showed marked relief of pain and notably decrease of 
the suprapubic and scrotal swelling.
DISCUSSION
In 1991, Sahin et al.1 described the first case of 
plasmocytoid variant urothelial carcinoma (PVUC) of 
the bladder in a 63-year-old-man presenting a bladder 
tumor and multiple lytic bone lesions with histologic 
appearance that mimicked multiple myeloma. This 
neoplasm is a rare variant of transitional cell carcinoma.
Recently, case series and case reports concerning 
this carcinoma variant have been published.2,3 Data 
regarding PVUC show that this neoplasm presents 
a distinctive clinical outcome represented by high 
aggressiveness and poor survival rate.2-4 The number 
of case reports increased during the last decade, what 
Figure 2. Photomicrography of the bladder tumor - A - Invasive carcinoma with plasmocytoid features (HE, 100X); 
B - Detail of tumor cells spread in single cell formation (HE, 200X); C and D - Detail of tumor cells spread in “Indian 
file” (HE, 400X).
Figure 1. Axial pelvic CT showing bladder wall 
thickening (arrow).
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raised the suspicion of an unrecognized ongoing 
causative factor or a better recognition of this variant 
could explain this increment.
Histopathological characteristics of PVUC 
show eccentrically placed nucleus and abundant 
eosinophilic cytoplasm. Nuclear grade are usually 
low to intermediate, with occasional pleomorphism. 
The tumor cells spread in single cell formation, 
known as “Indian file”, along nerve bundles.2,5,6 
Immunohistochemical profile of PVUC is characterized 
by positivity for CD138, a marker shared with myeloma 
cells. The cell adhesion marker E-cadherin is down-
regulated, suggesting a possible role of epithelial-
mesenchymal transition event in PVUC carcinogenesis. 
Loss of E-cadherin may also allow the discohesive 
nature of PVUC cells to invade into surrounding 
tissue, along fascial planes and draining lymph nodes.7 
MUM-1 positivity, which occurs in myeloma cells, has 
not been observed in PVUC.5
Immunohistochemical markers considered specific 
for urothelial lineage was observed in PVUC in an 
analysis involving variants of urothelial carcinoma, such 
Figure 3. Photomicrography of the bladder tumor - Immunohistochemistry. A - CD138 positive staining (400x); 
B - CK34BE12 positive staining (400x); C - E-cadherin negative staining (400x); D - p63 negative staining (400x).
Figure 4. Axial CT of the pelvis. A - showing densification of adipose tissue and muscle layers of the anterior 
abdominal (arrows); B - extension of the infiltration to the scrotum.
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as GATA3 (100%), S-100P (100%), Thrombomodulin 
(45%), CK7 (70%), CK20 (60%), p63(54%), HMCK 
(90%) and uroplakin (8%).8
Although retrospective cohorts studies of tertiary 
referral centers have been published, there is still 
paucity of published data on the clinical behavior and 
treatment of this malignancy.
In a recent retrospective analysis, Kaimakliotis et al.9 
analyzed 624 patients submitted to radical cystectomy 
from 2008 to 2013. Among them, 25 patients were 
diagnosed with PVUC. Positive paravesical margins, 
urethral surgical margins and lymph node involvement 
were higher in PVUC than in nonvariant subtype. These 
results indicated more aggressiveness of local spread 
and called attention for surgeons and pathologists on 
surgical margins in PVUCs.9
Local treatment for non muscle-invasive bladder 
urothelial carcinoma is based on transurethral resection 
with or without intravesical BCG therapy according 
to high risk factors. Some authors, however, tend 
to recommend early cystectomy in patients with 
other urothelial carcinoma variants, such as PVUC, 
due to the high risk of relapse and aggressive local 
dissemination.10
Similarly, there is no standard recommendation 
for initial management of locally-advanced or muscle-
invasive PVUC. Dayyani et al.3 reported the MD 
Anderson Cancer Center experience with 31 patients 
with PVUC. Sixteen patients had potentially surgically 
resectable tumor, 5 of them received neoadjuvant 
chemotherapy, 10 underwent initial surgery and 1 
was treated with transurethral resection. Among the 
patients who received neoadjuvant chemotherapy, 
pathological down staging was present in 80%. 
However, there was no difference in the survival 
rate between patients that received initial surgery or 
neoadjuvant chemotherapy. The median survival rate 
of this cohort was 17.7 months; 45.8 months for 
stages I-III and 13.3 months for stage IV. Patients with 
metastatic disease at presentation were treated with 
chemotherapy and showed the median survival rate 
of 12.6 months. In this cohort the peritoneum was a 
common site of recurrence (19 of 23 patients).
In other cohort of patients with muscle-invasive 
bladder tumor after cystectomy, median overall survival 
rate of patients with PVUC was 22 months, which was 
significantly lower comparing with patients with non-
variant carcinoma. Therefore, among patients selected 
for cystectomy, those with PVUC had increased risk of 
mortality at cystectomy.11
Polychemotherapy regimen MVAC has improved 
survival and overall response rate in comparison with 
single-agent cisplastin in randomized phase III trial 
for metastatic or unresectable urothelial bladder 
carcinoma.12 There is no consensus nor strong evidence 
regarding the use of specific chemotherapeutic agents 
in PVUC. However, in the present case, MVAC regimen 
provided rapid symptoms relief associated with 
reasonable tolerance.
The aggressive behavior of the present case is 
in accordance with the literature showing the poor 
outcome associated with PVUC. Chemotherapy may 
play a role in disease control and relief of symptoms 
in unresectable or recurrent disease, as showed in the 
Figure 5. A - Carcinoma infiltration of the subcutaneous adipose tissue (HE x 100); B - poorly cohesive and 
plasmocytoid features consistent with metastatic plasmacytoid carcinoma (HE x400).
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present case. However, neoadjuvant chemotherapy 
did not seem to impact in long-term survival in the 
retrospective cohort aforementioned.11
We believe that early diagnosis and radical surgical 
approach are pivotal for modifying the clinical course of 
this subtype of bladder carcinoma. A multidisciplinary 
team in referral centers is the ideal scenario for 
managing PVUC treatment.
CONCLUSION
We presented a case of PVUC, a rare histological 
variant of urothelial bladder carcinoma. The patient’s 
clinical course is in accordance with the literature 
data in terms of locally aggressiveness of this tumor. 
Morphologic distinction of the plasmocytoid phenotype 
is critical for clinician awareness with regard to the risk 
for early regional and metastatic progression of the 
disease.
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